EVA1A facilitates glycolysis in esophageal squamous cell carcinoma to boost PLAU histone lactylation and dampen CD8 + T cell activity

BACKGROUND: Endogenous retrovirus group E member 1 (EVA1A) is expressed in various normal tissues and plays a role in tumor development. However, its function in esophageal squamous cell carcinoma (ESCC) and immune regulation remains unclear. RESEARCH DESIGN AND METHODS: T cell activity, glycolysis markers, lactate levels, and PLAU expression were assessed through flow cytometry, quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR), enzyme-linked immunosorbent (ELISA), lactate dehydrogenase (LDH) assays, and chromatin immunoprecipitation (ChIP). RESULTS: T cell activation induced by EVA1A silencing. CONCLUSION: T cells, suggesting that EVA1A has potential as a therapeutic target for ESCC.